Equillium ^{Priced, Nasdaq: EQ}

We are a biotechnology company leveraging deep understanding of immunobiology to develop products for severe immuno-inflammatory disorders. Our initial product candidate, EQ001, is a clinical-stage, first-in-class monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6 which modulates Teff cells which drive a number of immuno-inflammatory diseases across therapeutic areas including transplant science, systemic autoimmunity, pulmonary, neurologic, gastrointestinal, renal, vascular, ophthalmic and dermatologic disorders. We believe EQ001 may have broad therapeutic utility in treating a large and diverse set of severe immuno-inflammatory diseases.Our pipeline is focused on developing EQ001 for multiple severe immuno-inflammatory disorders. We plan to initiate a Phase 1b/2 clinical trial of EQ001 for the treatment of aGVHD (acute graft-versus-host disease) in early 2019, and expect top-line data from the Phase 1b part of this trial within 12 months of initiation. Our IND with the FDA for aGVHD was accepted in July 2018. Additionally, in the first half of 2019, we plan to commence a Phase 2 clinical trial of EQ001 for the treatment of cGVHD, initiate a proof-of-concept clinical trial for the treatment of severe asthma and select one or more additional indications for future development.